BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37023697)

  • 1. RIPK2 as a promising druggable target for autoimmune diseases.
    Zhao W; Leng RX; Ye DQ
    Int Immunopharmacol; 2023 May; 118():110128. PubMed ID: 37023697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RIPK2 NODs to XIAP and IBD.
    Topal Y; Gyrd-Hansen M
    Semin Cell Dev Biol; 2021 Jan; 109():144-150. PubMed ID: 32631784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RIPK2 inhibitors for disease therapy: Current status and perspectives.
    Tian E; Zhou C; Quan S; Su C; Zhang G; Yu Q; Li J; Zhang J
    Eur J Med Chem; 2023 Nov; 259():115683. PubMed ID: 37531744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
    Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
    J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
    Fan T; Ji Y; Chen D; Peng X; Ai J; Xiong B
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):282-293. PubMed ID: 36408835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
    Yuan X; Chen Y; Tang M; Wei Y; Shi M; Yang Y; Zhou Y; Yang T; Liu J; Liu K; Deng D; Zhang C; Chen L
    J Med Chem; 2022 Jul; 65(13):9312-9327. PubMed ID: 35709396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
    Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
    Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASKA technology-based pull-down method reveals a suppressive effect of ASK1 on the inflammatory NOD-RIPK2 pathway in brown adipocytes.
    Takayanagi S; Watanabe K; Maruyama T; Ogawa M; Morishita K; Soga M; Hatta T; Natsume T; Hirano T; Kagechika H; Hattori K; Naguro I; Ichijo H
    Sci Rep; 2021 Nov; 11(1):22009. PubMed ID: 34759307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postbiotics for NOD2 require nonhematopoietic RIPK2 to improve blood glucose and metabolic inflammation in mice.
    Cavallari JF; Barra NG; Foley KP; Lee A; Duggan BM; Henriksbo BD; Anhê FF; Ashkar AA; Schertzer JD
    Am J Physiol Endocrinol Metab; 2020 Apr; 318(4):E579-E585. PubMed ID: 32101030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
    Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
    Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and evaluation of novel thieno[2,3d]pyrimidine derivatives as potent and specific RIPK2 inhibitors.
    Misehe M; Šála M; Matoušová M; Hercík K; Kocek H; Chalupská D; Chaloupecká E; Hájek M; Boura E; Mertlíková-Kaiserová H; Nencka R
    Bioorg Med Chem Lett; 2024 Jan; 97():129567. PubMed ID: 38008339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target.
    Rivoal M; Dubuquoy L; Millet R; Leleu-Chavain N
    J Med Chem; 2023 Nov; 66(21):14391-14410. PubMed ID: 37857324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production.
    Nachbur U; Stafford CA; Bankovacki A; Zhan Y; Lindqvist LM; Fiil BK; Khakham Y; Ko HJ; Sandow JJ; Falk H; Holien JK; Chau D; Hildebrand J; Vince JE; Sharp PP; Webb AI; Jackman KA; Mühlen S; Kennedy CL; Lowes KN; Murphy JM; Gyrd-Hansen M; Parker MW; Hartland EL; Lew AM; Huang DC; Lessene G; Silke J
    Nat Commun; 2015 Mar; 6():6442. PubMed ID: 25778803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-mediated proteolysis of the cell death regulator RIPK1 and the host defense modulator RIPK2 in human aortic endothelial cells.
    Madrigal AG; Barth K; Papadopoulos G; Genco CA
    PLoS Pathog; 2012; 8(6):e1002723. PubMed ID: 22685397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
    Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
    EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assaying RIPK2 Activation by Complex Formation.
    Steinle H; Ellwanger K; Kufer TA
    Methods Mol Biol; 2022; 2523():133-150. PubMed ID: 35759195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RIPK2: a promising target for cancer treatment.
    You J; Wang Y; Chen H; Jin F
    Front Pharmacol; 2023; 14():1192970. PubMed ID: 37324457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?
    Bellinger DL; Lorton D
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold.
    Suebsuwong C; Dai B; Pinkas DM; Duddupudi AL; Li L; Bufton JC; Schlicher L; Gyrd-Hansen M; Hu M; Bullock AN; Degterev A; Cuny GD
    Eur J Med Chem; 2020 Aug; 200():112417. PubMed ID: 32505849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma.
    Li D; Tang L; Liu B; Xu S; Jin M; Bo W
    Aging (Albany NY); 2021 Mar; 13(7):10450-10467. PubMed ID: 33790054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.